How to design and launch a successful Clinical Trial Manufacturing.

The COVID-19 pandemic demonstrated that the mass production of vaccines is crucial for our healthcare system. In order to ...

CHO Plus, Inc. ( a leading developer of biopharmaceutical manufacturing technology, announces that U.S. Patent No. 12,270,055 ...

Spark Therapeutics Inc. has presented a proprietary adeno-associated viral (AAV) vector expressing an artificial miRNA targeting human α-synuclein (α-Syn) mRNA. Accumulation of misfolded and insoluble ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Cell And Gene Therapy Market Size and ForecastThe global cell and gene therapy market is projected to witness significant ...

IDT and Elegen partner to launch an early access program offering long, clonal gene synthesis and high-complexity genes up to ...

Cognition, the startup behind the viral AI programming tool Devin, has introduced a new low-cost plan to incentivize signups. When Cognition released Devin last year, the tool quickly blew up on ...